Scarica l'app Stockscreener
1.29
12.17%
0.14
Dopo l'orario di chiusura:
1.29
Precedente Chiudi:
$1.15
Aprire:
$1.14
Volume 24 ore:
832.08K
Relative Volume:
0.13
Capitalizzazione di mercato:
$28.89M
Reddito:
-
Utile/perdita netta:
$-16.28M
Rapporto P/E:
-0.0927
EPS:
-13.91
Flusso di cassa netto:
$-13.75M
1 W Prestazione:
+10.26%
1M Prestazione:
-12.24%
6M Prestazione:
+78.84%
1 anno Prestazione:
-59.05%
Intervallo 1D:
$1.14
$1.30
Intervallo di 1 settimana:
$1.085
$1.30
Portata 52W:
$0.281
$3.85
Pasithea Therapeutics Corp Stock (KTTA) Company Profile
Nome
Pasithea Therapeutics Corp
Settore
Industria
Telefono
(702) 514-4174
Indirizzo
1111 LINCOLN ROAD, SUITE 500, MIAMI BEACH
Confronta KTTA con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
KTTA
Pasithea Therapeutics Corp
|
1.29 | 25.76M | 0 | -16.28M | -13.75M | -13.91 |
|
VRTX
Vertex Pharmaceuticals Inc
|
453.36 | 115.12B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
771.87 | 81.34B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.65 | 52.48B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
840.95 | 51.59B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
174.04 | 37.13B | 447.02M | -1.18B | -906.14M | -6.1812 |
Pasithea Therapeutics Corp Borsa (KTTA) Ultime notizie
Pasithea Therapeutics Corp. (KTTA) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Pasithea Therapeutics Corp Stock Analysis and ForecastMomentum Trading Signals & Big Profit Low Capital - earlytimes.in
How Pasithea Therapeutics Corp. stock compares to industry benchmarks2025 Earnings Surprises & AI Powered Trade Plan Recommendations - Улправда
Pasithea Therapeutics Stock Soars After Positive Data From Cancer Drug Trial: Retail’s Elated - MSN
Can Pasithea Therapeutics Corp. stock hit analyst price targetsWeekly Stock Analysis & Safe Entry Momentum Stock Tips - Улправда
What sentiment indicators say about Pasithea Therapeutics Corp. Equity Warrant stockJuly 2025 Pullbacks & Reliable Entry Point Trade Alerts - Улправда
Is Pasithea Therapeutics Corp. Equity Warrant stock cheap at current valuationTrade Volume Summary & Weekly Sector Rotation Insights - Улправда
What is the fair value of Pasithea Therapeutics Corp. Equity Warrant stock nowQuarterly Portfolio Summary & Long-Term Growth Plans - Улправда
Is Pasithea Therapeutics Corp. Equity Warrant stock a dividend growth opportunityJuly 2025 Analyst Calls & High Accuracy Swing Trade Signals - Улправда
Will Pasithea Therapeutics Corp. stock return to pre crisis levelsWeekly Investment Report & Fast Gaining Stock Strategy Reports - Улправда
What hedge fund activity signals for Pasithea Therapeutics Corp. Equity Warrant stockLong Setup & Accurate Entry and Exit Point Alerts - Улправда
Recap Report: What sentiment indicators say about Pasithea Therapeutics Corp. Equity Warrant stockTrade Analysis Report & Daily Oversold Stock Bounce Ideas - Улправда
Pasithea Therapeutics Regains Nasdaq Compliance - The Globe and Mail
Pasithea Therapeutics regains Nasdaq compliance - MSN
Pasithea Therapeutics regains Nasdaq compliance with minimum bid price rule - Investing.com
Pasithea Therapeutics (NASDAQ: KTTA) back in Nasdaq bid price compliance - Stock Titan
Market Review: Is Pasithea Therapeutics Corp stock a contrarian buy2025 Top Gainers & Safe Capital Allocation Plans - moha.gov.vn
LEAHY EMER Insider Trades - Nasdaq
SCHNEIDERMAN DANIEL H Insider Trades - Nasdaq
JANUS HENDERSON GROUP PLC Acquires Significant Stake in Pasithea Therapeutics Corp - GuruFocus
Pasithea Therapeutics (NASDAQ:KTTA) Upgraded at Zacks Research - Defense World
Why Did KTTA Stock Soar A Whopping 48% Today? - MSN
What is HC Wainwright’s Forecast for KTTA FY2025 Earnings? - Defense World
HC Wainwright Begins Coverage on Pasithea Therapeutics (NASDAQ:KTTA) - Defense World
There is no way Pasithea Therapeutics Corp (KTTA) can keep these numbers up - setenews.com
Pasithea Therapeutics stock initiated with Buy rating at H.C. Wainwright By Investing.com - Investing.com Nigeria
HC Wainwright & Co. Initiates Coverage of Pasithea Therapeutics (KTTA) with Buy Recommendation - Nasdaq
Pasithea Therapeutics stock initiated with Buy rating at H.C. Wainwright - Investing.com
HC Wainwright Initiates Coverage on Pasithea Therapeutics With Buy Rating, $3 Price Target - marketscreener.com
MSN Money - MSN
Is Pasithea Therapeutics Corp. stock attractive for hedge funds2025 Top Decliners & Technical Confirmation Trade Alerts - Newser
Small Cap Stocks To ConsiderNovember 30th - MarketBeat
Will Pasithea Therapeutics Corp. Equity Warrant stock benefit from commodity prices2025 Dividend Review & Weekly Top Performers Watchlists - Newser
Insiders Buying Pasithea Therapeutics Might Wish They Invested More, Stock Gains 10% - Yahoo Finance
Pasithea Therapeutics Reaches US$104m Market Cap Benefiting Insider Stock Buying - simplywall.st
Lawrence Steinman Bought 201% More Shares In Pasithea Therapeutics - Yahoo Finance
Pasithea Therapeutics Completes $60M Public Offering - MSN
Will Pasithea Therapeutics Deliver On Clinical Promise Or Struggle With Funding Risks? - RTTNews
Small Cap Stocks To Follow NowNovember 29th - MarketBeat
Best Small Cap Stocks To Keep An Eye OnNovember 28th - MarketBeat
Best Penny Stocks To Watch TodayNovember 29th - MarketBeat
Pasithea Therapeutics announces closing of $60 million public offering of common stock - marketscreener.com
Pasithea Therapeutics (Nasdaq: KTTA) raises $60M, extends cash runway into 2028 - Stock Titan
Promising Penny Stocks To Consider – November 30th - Defense World
Small Cap Stocks To Consider – November 30th - Defense World
Published on: 2025-12-02 03:15:38 - Newser
Biotech Stocks To Watch Today – November 30th - Defense World
Pasithea Therapeutics (KTTA) Stock Analysis Report | Financials & Insights - Benzinga
Pasithea Therapeutics Corp Azioni (KTTA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Pasithea Therapeutics Corp Azioni (KTTA) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Marques Tiago | Chief Executive Officer |
Nov 28 '25 |
Buy |
0.75 |
33,333 |
25,000 |
73,334 |
| Dumesnil Simon | Director |
Nov 28 '25 |
Buy |
0.75 |
33,333 |
25,000 |
35,833 |
0.90%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):